DOGWOOD THERAPEUTICS INC. - COMMON STOCK

Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

21 يناير 2025 08:15:00 بحسب Nasdaq GlobeNewswire

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

18 نوفمبر 2024 07:45:00 بحسب Nasdaq GlobeNewswire

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

07 نوفمبر 2024 06:05:00 بحسب Nasdaq GlobeNewswire

Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024

31 أكتوبر 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

30 أكتوبر 2024 08:15:00 بحسب Nasdaq GlobeNewswire